MacuLogix Secures $3.6M Series A

MacuLogix, the developer of tools for diagnosis of age-related macular degeneration (AMD), has closed a $3.6 million Series A round of financing. The Hummelstown, PA-based company is developing the AdaptDx, an automated device that will be the first practical diagnostic for early detection and tracking of AMD. MacuLogix will use the funding to accelerate manufacturing and commercial sales of the AdaptDx. The financing included participation from investors Berwind Private Equity, Roche Venture Fund, Life Sciences Greenhouse of Central Pennsylvania and Ben Franklin Technology Partners.

View details

News & Analysis

Related content